238 related articles for article (PubMed ID: 16889960)
61. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
Rempel V; Volz N; Hinz S; Karcz T; Meliciani I; Nieger M; Wenzel W; Bräse S; Müller CE
J Med Chem; 2012 Sep; 55(18):7967-77. PubMed ID: 22916707
[TBL] [Abstract][Full Text] [Related]
62. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
63. The effects of charge-neutralizing mutation D6.30N on the functions of CB1 and CB2 cannabinoid receptors.
Nebane NM; Kellie B; Song ZH
FEBS Lett; 2006 Oct; 580(22):5392-8. PubMed ID: 16989818
[TBL] [Abstract][Full Text] [Related]
64. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
Wilkinson JD; Williamson EM
J Dermatol Sci; 2007 Feb; 45(2):87-92. PubMed ID: 17157480
[TBL] [Abstract][Full Text] [Related]
65. Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
Han S; Zhang FF; Qian HY; Chen LL; Pu JB; Xie X; Chen JZ
Eur J Med Chem; 2015 Mar; 93():16-32. PubMed ID: 25644673
[TBL] [Abstract][Full Text] [Related]
66. Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists.
Kang SY; Lee SH; Seo HJ; Jung ME; Ahn K; Kim J; Lee J
Bioorg Med Chem Lett; 2008 Apr; 18(7):2385-9. PubMed ID: 18337096
[TBL] [Abstract][Full Text] [Related]
67. Synthesis and in vitro evaluation of novel 2-oxo-1,2-dihydroquinoline CB2 receptor inverse agonists.
Raitio KH; Savinainen JR; Nevalainen T; Järvinen T; Vepsäläinen J
Chem Biol Drug Des; 2006 Dec; 68(6):334-40. PubMed ID: 17177896
[TBL] [Abstract][Full Text] [Related]
68. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
Ermann M; Riether D; Walker ER; Mushi IF; Jenkins JE; Noya-Marino B; Brewer ML; Taylor MG; Amouzegh P; East SP; Dymock BW; Gemkow MJ; Kahrs AF; Ebneth A; Löbbe S; O'Shea K; Shih DT; Thomson D
Bioorg Med Chem Lett; 2008 Mar; 18(5):1725-9. PubMed ID: 18255291
[TBL] [Abstract][Full Text] [Related]
69. Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives.
Turkman N; Shavrin A; Ivanov RA; Rabinovich B; Volgin A; Gelovani JG; Alauddin MM
Bioorg Med Chem; 2011 Sep; 19(18):5698-707. PubMed ID: 21872477
[TBL] [Abstract][Full Text] [Related]
70. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.
Onaivi ES; Ishiguro H; Gong JP; Patel S; Perchuk A; Meozzi PA; Myers L; Mora Z; Tagliaferro P; Gardner E; Brusco A; Akinshola BE; Liu QR; Hope B; Iwasaki S; Arinami T; Teasenfitz L; Uhl GR
Ann N Y Acad Sci; 2006 Aug; 1074():514-36. PubMed ID: 17105950
[TBL] [Abstract][Full Text] [Related]
71. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis.
Ryckmans T; Edwards MP; Horne VA; Correia AM; Owen DR; Thompson LR; Tran I; Tutt MF; Young T
Bioorg Med Chem Lett; 2009 Aug; 19(15):4406-9. PubMed ID: 19500981
[TBL] [Abstract][Full Text] [Related]
72. Cannabimimetic indoles, pyrroles and indenes.
Huffman JW
Curr Med Chem; 1999 Aug; 6(8):705-20. PubMed ID: 10469887
[TBL] [Abstract][Full Text] [Related]
73. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
74. Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors.
Ferrarini PL; Calderone V; Cavallini T; Manera C; Saccomanni G; Pani L; Ruiu S; Gessa GL
Bioorg Med Chem; 2004 Apr; 12(8):1921-33. PubMed ID: 15051060
[TBL] [Abstract][Full Text] [Related]
75. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'.
Papahatjis DP; Nikas SP; Kourouli T; Chari R; Xu W; Pertwee RG; Makriyannis A
J Med Chem; 2003 Jul; 46(15):3221-9. PubMed ID: 12852753
[TBL] [Abstract][Full Text] [Related]
76. Characterization of human cannabinoid CB2 receptor coupled to chimeric Galpha(qi5) and Galpha(qo5) proteins.
Malysz J; Daza AV; Kage K; Grayson GK; Yao BB; Meyer MD; Gopalakrishnan M
Eur J Pharmacol; 2009 Jan; 603(1-3):12-21. PubMed ID: 19071106
[TBL] [Abstract][Full Text] [Related]
77. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
Khanolkar AD; Lu D; Ibrahim M; Duclos RI; Thakur GA; Malan TP; Porreca F; Veerappan V; Tian X; George C; Parrish DA; Papahatjis DP; Makriyannis A
J Med Chem; 2007 Dec; 50(26):6493-500. PubMed ID: 18038967
[TBL] [Abstract][Full Text] [Related]
78. Design, synthesis, and biological evaluation of novel alkenylthiophenes as potent and selective CB1 cannabinoid receptor antagonists.
Tai CL; Hung MS; Pawar VD; Tseng SL; Song JS; Hsieh WP; Chiu HH; Wu HC; Hsieh MT; Kuo CW; Hsieh CC; Tsao JP; Chao YS; Shia KS
Org Biomol Chem; 2008 Feb; 6(3):447-50. PubMed ID: 18219411
[TBL] [Abstract][Full Text] [Related]
79. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
[TBL] [Abstract][Full Text] [Related]
80. Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors.
Sikazwe D; Bondarev ML; Dukat M; Rangisetty JB; Roth BL; Glennon RA
J Med Chem; 2006 Aug; 49(17):5217-25. PubMed ID: 16913710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
